Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet, Laurent
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. [electronic resource] - World journal of gastroenterology Apr 2007 - 2328-32 p. digital
Publication Type: Clinical Trial; Journal Article
1007-9327
10.3748/wjg.v13.i16.2328 doi
Adalimumab
Adult
Anti-Inflammatory Agents--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
C-Reactive Protein--metabolism
Colitis, Ulcerative--blood
Drug Tolerance
Female
Humans
Infliximab
Injections, Subcutaneous
Male
Middle Aged
Prospective Studies
Remission Induction
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. [electronic resource] - World journal of gastroenterology Apr 2007 - 2328-32 p. digital
Publication Type: Clinical Trial; Journal Article
1007-9327
10.3748/wjg.v13.i16.2328 doi
Adalimumab
Adult
Anti-Inflammatory Agents--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
C-Reactive Protein--metabolism
Colitis, Ulcerative--blood
Drug Tolerance
Female
Humans
Infliximab
Injections, Subcutaneous
Male
Middle Aged
Prospective Studies
Remission Induction